Kaihang Zhong Yuyan Xu Yuan Cheng Yaohong Wen Lei Cai Guolin He Huakun Huang Shunjun Fu Xuefeng Zhong Yating Zheng Tingting Chen Mengli Huang Mingxin Pan
10.3389/fimmu.2022.999763
Front Immunol
2022 Aug 31;13:999763.
combined immunotherapy hepatocellular carcinoma (hcc) portal vein tumor thrombus (pvtt) tertiary lymphoid structure (tls) tumor immune microenvironment (time)
CC BY
https://pubmed.ncbi.nlm.nih.gov/36119069/
Carcinoma, Hepatocellular / complications Carcinoma, Hepatocellular / pathology Carcinoma, Hepatocellular / therapy Liver Neoplasms / complications Liver Neoplasms / pathology Liver Neoplasms / therapy Thrombosis / pathology
Carcinoma, Hepatocellular / complications Carcinoma, Hepatocellular / pathology Carcinoma, Hepatocellular / therapy Liver Neoplasms / complications Liver Neoplasms / pathology Liver Neoplasms / therapy Thrombosis / pathology Case Reports Research Support, Non-U.S. Gov't Humans Immunotherapy Middle Aged Portal Vein / pathology Sorafenib / therapeutic use Tumor Microenvironment Sorafenib
PMC9471014
36119069
Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy
2022